Breast cancer treatment is changing at an unprecedented pace.
In Episode 3 of Cancer Unfiltered, Dr. Komal Jhaveri and Dr. Neil Iyengar discuss the latest FDA approvals, landmark clinical trials, and emerging treatment strategies that are reshaping care across HR-positive, HER2-positive, and triple-negative breast cancer. From practice-changing DESTINY data to the expanding role of antibody-drug conjugates, this episode breaks down what the latest evidence means for treatment decisions today.
Topics discussed:
• Six new FDA approvals across all major breast cancer subtypes
• Vepdegestrant and the VERITAC-2 trial for ESR1-mutant HR-positive breast cancer
• DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09: key findings and clinical impact
• The growing role of antibody-drug conjugates (ADCs) in first-line metastatic triple-negative breast cancer
• Treatment sequencing and how new approvals are changing clinical decision-making
• Which HER2-positive patients may benefit most from the DESTINY-Breast09 approach
• Brain metastases, PIK3CA mutations, and selecting therapy for high-risk patients
• Giredestrant and the lidERA trial: improving endocrine therapy options
• VIKTORIA-1 and emerging therapies targeting the PI3K/AKT/mTOR (PAM) pathway
• The future of breast cancer treatment and practice-changing data to watch
Whether you're an oncologist, advanced practice provider, researcher, or healthcare professional, this episode offers practical insights into the rapidly evolving breast cancer treatment landscape and what these developments mean for patient care.
▶️ Watch on YouTube - https://youtu.be/m0l8feuG6Y8
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox, & iHeartRadio - https://linkin.bio/cancerunfiltered
Cancer Unfiltered is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.
#CancerUnfiltered #BreastCancer #Oncology #MedicalOncology #FDAApprovals #DESTINYBreast11 #DESTINYBreast05 #Vepdegestrant #TripleNegativeBreastCancer #HER2Positive #CancerPodcast #CommunityHealthMedia